CIITA and breast carcinoma: This is in line with reports demonstrating a frequent promoter methylation of CIITA in different cancer types that was associated with an impaired HLA class II expression and could not be reverted by IFN-γ, but by demethylating agents [77], as shown for ovarian cancer [78], diffuse large B-cell lymphoma [79] and breast cancer [80].